- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06351475
Eficacia del uso intraoperatorio de albúmina al 20% combinada con lactato de Ringer versus lactato de Ringer durante la cirugía citorreductora con quimioterapia intraperitoneal hipertérmica: protocolo para un ensayo clínico aleatorizado y abierto (ALBUCHIP)
Evaluación de la eficacia del Remplissage Vasculaire Par de l'ALBUmine Humaine 20% + Ringer Lactate comparé au Ringer Lactate Seul Chez Les Patients opérés Par cytoréduction Avec CHimiothérapie Intrapéritonéale hyPerthermique
Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day.
Methods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.
Recruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Information notice and consent form will be delivered. The day before the surgery, anaesthesiologist who will conduct the pre anaesthetic visit will be able to include patients in the study (=inclusion visit). Randomisation will be done at the inclusion visit after information and signature of consent form of voluntary patients. A randomization number will be assigned. The 1:1 randomisation will be centralized via an online interface ensuring secret group assignment, and based on predefined randomisation lists with variable-size permutation blocks, stratified by center. Randomisation will be accomplished using a computer-generated random sequence.
Randomized Open, Blinded endpoint (PROBE) design. This study is a randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.
Intervention
- 20% Albumin + Ringer Lactate group (intervention group) Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
- Control group Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.
Outcome measures The primary outcome will be the Comprehensive Complication Index (CCI score) at day 28 after CRS with HIPEC. Secondary outcomes are mortality at day 28, CCI score at day 7, volume of intra operative and post operative (48h) post operative fluid therapy, cumulated incidence of surgical post operative complications, cumulated incidence of medical post operative complications, need for mechanical ventilation, renal replacement therapy between surgery and day 28, SOFA score variation between pre operative period and 48h after surgery, number of days alive out of intensive care unit and out of hospital until day 28
Sample size calculation To ensure a power of 80%, a number of patients 130 (65 patients by group) will be necessary with a reduction of 13.6 (SD 24) points of the CCI score at day 28 in the intervention group. Because of a risk of neoplastic evolution between anaesthetic consultation and randomisation (10% of early cancellation), a total of 146 patients (73 by group) will be included in the study.
Discussion In summary, ALBUCHIP study will be the first randomized clinical trial assessing efficacy of intraoperative use of 20% albumin combined with Ringer Lactate versus Ringer Lactate during CRS with HIPEC. Results yielded from this study will be helpful for vascular filling during CRS with HIPEC but, thanks to ancillary studies, to improve pathophysiological understanding of this surgery.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jérôme Lambert, Pr
- Número de teléfono: +33 142499742
- Correo electrónico: jerome.lambert@u-paris.fr
Copia de seguridad de contactos de estudio
- Nombre: Arthur Moreau, Dr
- Número de teléfono: +33 142499394
- Correo electrónico: arthur.moreau@aphp.fr
Ubicaciones de estudio
-
-
-
Lyon, Francia
- Reclutamiento
- Hôpital Lyon Sud Pierre Bénite
-
Contacto:
- Anne Li
- Número de teléfono: +33 04 78 86 14 76
- Correo electrónico: anne.li@chu-lyon.fr
-
Montpellier, Francia
- Reclutamiento
- Institut régional du Cancer de Montpellier
-
Contacto:
- Lana Zoric
- Número de teléfono: +33 467618538
- Correo electrónico: Lana.Zoric@icm.unicancer.fr
-
Paris, Francia, 75013
- Reclutamiento
- La Pitié Salpetriere hospital
-
Contacto:
- Alexandre Sitbon
- Número de teléfono: +33 184827399
- Correo electrónico: alexandre.sitbon@aphp.fr
-
Paris, Francia
- Reclutamiento
- Lariboisière hospital
-
Contacto:
- Nathalie Poirier
- Número de teléfono: +33 1 49 95 68 43
- Correo electrónico: nathalie.poirier@aphp.fr
-
Paris, Francia
- Reclutamiento
- Saint Louis hospital
-
Contacto:
- Arthur Moreau
- Número de teléfono: +33 142499394
- Correo electrónico: arthur.moreau@aphp.fr
-
Reims, Francia
- Reclutamiento
- Robert Debré hospital
-
Contacto:
- Ezechiel Bankole
- Número de teléfono: +33 326788801
- Correo electrónico: ebankole@chu-reims.fr
-
Strasbourg, Francia
- Reclutamiento
- Hôpital Hautepierre / UIC ARMO
-
Contacto:
- Valentina FAITOT
- Número de teléfono: +33 388116768
- Correo electrónico: valentina.faitot@chru-strasbourg.fr
-
Villejuif, Francia
- Reclutamiento
- Gustave Roussy Institute
-
Contacto:
- Stéphanie Suria
- Número de teléfono: +33 142114437
- Correo electrónico: Stephanie.SURIA@gustaveroussy.fr
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male and female patients aged 18 years old and older
- Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)
- Patient volunteer for the study and provided written informed consent
- Patient affiliated to the French Health Insurance
Exclusion Criteria:
- Adults >75 years old
- Functional status rendering the patient ineligible for cytoreduction with CHIP (ECOG > 2 or Karnofsky index < 75)
- Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)
- Severe preoperative hypoalbuminemia (albuminemia < 20 g/L)
- History of chronic left heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction < 40%)
- Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)
- Significant ascites with preoperative respiratory repercussions
- Uncontrolled diabetes (HbA1c > 8.5%)
- Allergy to exogenous human albumin and its excipients.
- Contraindication to the administration of Ringer's lactate (history of allergy)
- Hyperkalemia > 6.0 mmol/L
- Hypercalcemia (total calcium > 2.60 mmol/L)
- Chronic use of digitalis and hyperkalemic diuretics
- Pregnancy, breastfeeding
- Known preoperative renal failure (GFR < 30 mL/min/1.73m2 or extrarenal purification)
- Recent brain trauma < 6 months (traumatic, ischemic, or hemorrhagic)
- Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable
- Patient deprived of liberty
- Patient under guardianship or curatorship
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 20% Albumin + Ringer Lactate group
Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery. |
Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery. |
|
Comparador activo: Control group
Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned. |
Ringer lactate |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Comprehensive Complication Index score
Periodo de tiempo: At day 28
|
The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death |
At day 28
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Volumen de fluidoterapia intraoperatoria y posoperatoria.
Periodo de tiempo: 48 horas después de la cirugía
|
48 horas después de la cirugía
|
|
|
Incidencia acumulada de complicaciones postoperatorias quirúrgicas
Periodo de tiempo: Hasta el día 28
|
Hasta el día 28
|
|
|
Número de días con vida fuera de la unidad de cuidados intensivos
Periodo de tiempo: Hasta el día 28
|
Hasta el día 28
|
|
|
Número de días con vida fuera del hospital
Periodo de tiempo: Hasta el día 28
|
Hasta el día 28
|
|
|
Incidencia de complicaciones infecciosas
Periodo de tiempo: Hasta el día 28
|
Hasta el día 28
|
|
|
Incidencia de complicaciones médicas
Periodo de tiempo: Hasta el día 28
|
Hasta el día 28
|
|
|
Incidencia acumulada de muerte en unidad de cuidados intensivos
Periodo de tiempo: Hasta el día 28
|
Hasta el día 28
|
|
|
Incidencia acumulada de muerte en hospital
Periodo de tiempo: Hasta el día 28
|
Hasta el día 28
|
|
|
Número de días bajo vasopresores
Periodo de tiempo: Hasta el día 28
|
Hasta el día 28
|
|
|
Proporción de pacientes con complicaciones alérgicas a la albúmina
Periodo de tiempo: En el día 133
|
En el día 133
|
|
|
Comprehensive Complication Index score
Periodo de tiempo: At day 7
|
The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death |
At day 7
|
|
Number of days under mechanical ventilation outside the operating room
Periodo de tiempo: Up to day 28
|
Between surgery and day 28 |
Up to day 28
|
|
Number of days under renal replacement therapy
Periodo de tiempo: Up to day 28
|
Between surgery and day 28 |
Up to day 28
|
|
Sequential organ failure assessment (SOFA) score variation
Periodo de tiempo: 48 hours after surgery
|
Between pre operative period and 48h after surgery |
48 hours after surgery
|
|
SOFA score
Periodo de tiempo: At day 28
|
Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function |
At day 28
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- APHP230864
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .